Content Status
Type
Linked Node
Rationale for Grouping of Anti-TB Drugs
Learning ObjectivesRationale for Grouping of Anti-TB Drugs
H5Content
Content
The anti-TB drugs recommended for the treatment of Multi-drug Resistant (MDR)/ Rifampicin-resistant Tuberculosis (RR-TB) patients are grouped based on their efficacy, safety, experience of use of the drug and drug class.
| DRUG GROUP | REASONS FOR INCLUSION IN THE CLASSIFICATION OF ANTI-TB DRUGS |
|---|---|
| Group A: Fluoroquinolones (levofloxacin and moxifloxacin), bedaquiline and linezolid | Considered highly effective and strongly recommended for inclusion in all regimens unless contraindicated |
| Group B: Clofazimine and cycloserine or terizidone | Conditionally recommended as agents of the second choice based on their efficacy and safety |
| Group C: This includes all other medicines that can be used when a regimen cannot be composed with Group A and B agents | Ranked and included by the relative balance of benefit to harm usually expected of each |
Resources
- Guidelines for Programmatic Management of Drug-resistant Tuberculosis in India, March 2021.
- WHO Consolidated Guidelines on Tuberculosis: Module 4 - Treatment: Drug-resistant TB Treatment, 2020.
- Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis, 2014.
Kindly provide your valuable feedback on the page to the link provided HERE
LMS Page Link
Content Creator
Reviewer
- Log in to post comments